AVEO - AVEO Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

AVEO Pharmaceuticals, Inc.

One Broadway
14th Floor
Cambridge, MA 02142
United States
617-588-1960
http://www.aveooncology.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees19

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael P. BaileyCEO, Pres & Director701.31kN/A1965
Mr. Matthew D. DallasChief Financial OfficerN/AN/A1975
Dr. Michael N. NeedleChief Medical Officer619.49kN/A1960
Dr. Nikhil Mehta Ph.D.Sr. VP of Regulatory & Quality AssuranceN/AN/A1959
Dr. Emile Farhan Ph.D.VP of Technical OperationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase 3 TIVO-3 trial of tivozanib for the treatment of advanced RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor, for the treatment of advanced RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody, in Phase I and Phase II clinical trials in squamous cell carcinoma of the head and neck, metastatic pancreatic ductal cancer, and acute myeloid leukemia; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. It has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

Corporate Governance

AVEO Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.